Pharmacists could use bulk ingredients in compounded medicines if they meet quality and safety checks, including records of their source and testing.
The proposal would let pharmacists use bulk ingredients in medicines they compound if the ingredients meet listed quality, source, and safety-check rules.
The proposal would limit regular or large-scale compounding of human medicines that copy available commercial drugs, with exceptions for documented patient needs, shortages, or urgent treatment.
The proposal would bar human-use compounding with certain ingredients, including those in drugs the FDA withdrew for safety or effectiveness, within the scope of that withdrawal.
The proposal would require pharmacies to keep compounding records, with extra ingredient and testing details for batch-made medicines and medicines made with bulk ingredients.
Pharmacists may use bulk drug substances to make compounded medicines. These conditions apply when pharmacists use bulk drug substances in compounding. The substance must meet at least one listed drug-standard or FDA qualification, be pharmaceutical grade, and come with a certificate of analysis. The pharmacist must document a qualifying FDA inspection of the manufacturer within the past two years and conduct or obtain quality testing. A different supplier may be used if the Board and FDA approve it and the pharmacist can show purity and safety by reasonable means.
Pharmacists may not regularly compound, or compound excessive amounts of, human medicines that are essentially copies of available commercial drugs. The restriction covers human medicines that copy an FDA-approved drug not listed as discontinued. Exceptions include a patient-specific change that makes a clinically significant difference, a drug shortage or unavailability, an urgent need, or mixing two or more available products. For a patient-specific clinical difference, the prescriber must document a medical reason other than cost or convenience and explain how the compounded medicine would address it. A prefilled form or automated note is not enough.
Pharmacists may not compound a human medicine containing a bulk substance that the FDA withdrew for safety or that is covered by an effective, unapproved investigational drug application. This restriction applies to compounding for human use. The restriction for an FDA-withdrawn drug applies only to the scope of the FDA withdrawal for safety or effectiveness.
Pharmacists must keep compounding records and provide them for Board inspection or audit. These requirements cover pharmacists and pharmacies that compound medicines. Records for medicines made in batches or with bulk ingredients must include added details about ingredients, lots, quantities, beyond-use dates, and quality testing. Pharmacies must keep a full formula when needed to repeat a complex preparation and a written quality plan with records of staff training, equipment checks, environmental monitoring, and applicable testing. Requested records must be available within 48 hours, or within another reasonable time the Board sets based on the request.
No hearings or votes scheduled.